Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization

Table 2 Characteristics of patients in the total cohort

Parameter1	Value
Age (yr)	64.24 ± 10.35
Sex (M) (%)	124 (74.25)
Cirrhosis (yes) (%)	134 (80.24)
AFP (ng/dL)	1769.49 ± 7297.65
AFP (median, range)	53.80 (1-66000)
AFP > 100 (%)	54 (40.60)
Number nodules	1.95 ± 1.39
MTD (cm)	4.45 ± 2.64
PVT (yes) (%)	24 (14.37)
Aggressiveness index score (%)
Score > 4	75 (63.56)
Total bilirubin (mg/dL)	1.23 ± 0.80
ALKP (IU/mL)	133.29 ± 74.74
GGTP (IU/mL)	152.26 ± 152.80
AST (IU/L)	104.68 ± 110.73
ALT (IU/L)	77.85 ± 88.25
Albumin (g/dL)	3.63 ± 1.93
Platelet count (× 109/L)	113.78 ± 82.70
WBC (× 109/L)	5.46 ± 2.59
Lymphocyte (× 109/L)	1.41 ± 0.98
Survival time (median, range)	38 (3-175)

¹All values: mean ± SD for continuous variables; Aggressiveness Index (sum of scores): MTD (in tertiles): MTD < 4.5; 4.5 ≤ MTD ≤ 9.6; MTD > 9.6; scores 1, 2, 3 respectively; AFP (cut-off): AFP < 100; 100 ≤ AFP ≤1000; AFP > 1000; scores 1, 2, 3 respectively; PVT (no/yes): PVT (no); PVT (yes); scores 1, 3 respectively; Nodules (number): Nodules ≤ 3; Nodules > 3; scores 1, 3 respectively. AFP: Alpha-fetoprotein; MTD: Maximum tumor diameter; PVT: Portal vein thrombosis; ALKP: Alkaline phosphatase; GGTP: Gamma glutamyl transpeptidae; AST: Aspartate aminotransaminase; ALT: Alanina amminotransferasi; Hb: Haemoglobin; WBC: White blood cell.